QTTB earnings

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patients in Part A open-label extension (OLE) ongoing -- -- Cash and cash equivalents of $49.0 million as of September 30, 2025 expected to provide financial runway into 2027 -- WALTHAM, Mass., Nov. 13, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended September 30, 2025, and provided

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.

WALTHAM, Mass., Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m. E.T. on Thursday, September 4th at the 2025 Wells Fargo Healthcare Conference. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event. About Q32 Bio Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of

-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment of Adrien Sipos, M.D., Ph.D., an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, as Interim Chief Medical Officer -- -- Cash and cash equivalents of $54.8 million as of June 30, 2025, which is now expected to provide financial runway into 2027 -- WALTHAM, Mass., Aug. 6, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflamm

-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass., June 25, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departing the company. "Adrien has a proven track record of success in roles that span clinical development and medical affai

-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H'26 -- WALTHAM, Mass., May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alope

WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program. "The Fast Track designation granted by the FDA recogn

-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA). "Dosing the first patients in both the Part A OLE and Part B of our SIGNAL-AA trial highlights our ongoing momentum in the clinical development of bempikibart as

-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension (OLE) and SIGNAL-AA Part B on track to dose patients in 1H'25; SIGNAL-AA Part B topline data on-track for 1H'26 -- -- Cash and cash equivalents of $78.0 million as of December 31, 2024 expected to provide financial runway into 2H'26 -- WALTHAM, Mass., March 11, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a cli

-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing -- -- In the Phase 2a clinical trial, bempikibart was observed to be safe and well-tolerated, with PK supporting subcutaneous dosing and receptor occupancy data demonstrating desired target engagement; clinical biomarkers showed

-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass., Feb. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando, FL. B

WALTHAM, Mass., Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferenceDate: Wednesday, March 5, 2025Presentation Time: 11:50 a.m. E.T.Location: Boston, MA Leerink Partners Global Healthcare ConferenceDate: Tuesday, March 11, 2025Fireside Chat Presentation Time: 11:20 a.m. E.T.Location: Miami Beach, FL A webcast of the presentations will be available on the Events and Presentations page of Q32 Bio's website at www.Q32Bio.com. Ar

-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 -- -- Company to discontinue renal basket trial for ADX-097 to conserve resources and evaluate strategic options for its tissue-targeted complement inhibitor platform -- -- Cash runway expected to extend to 2H'26 -- WALTHAM, Mass., Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore

WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a virtual company presentation at 4:00 p.m. E.T. on Tuesday, February 11, 2025 at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the

-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response -- -- SIGNAL-AD Phase 2a clinical trial in atopic dermatitis demonstrated promising findings in Part A but did not meet primary endpoint in Part B -- -- Across both trials, bempikibart was observed to be safe and well tolerated; demonstrated potent IL-7 and TSLP inhibition via changes in both Th2 biomarkers and T-cells, and desired target engagement -- -- Based on these results, Company plans to advance bempikibart in patients with AA -- WALTHAM, Mass., Dec. 10, 2024 /PRNewswire/ -- Q32

WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m. E.T. on Tuesday, November 12, 2024 at Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event. About Q32 Bio Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent reg

WALTHAM, Mass., Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: Thursday, September 5, 2024Location: New York, NY 2024 Cantor Fitzgerald Global Healthcare ConferenceDate: Tuesday, September 17, 2024Presentation Time: 3:40 p.m. E.T.Location: New York, NY Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Presentation Time: 11:30 a.m. E.T.Location: Virtual A webc